NasdaqGS:INSMBiotechs
Rising Institutional Interest and Brinsupri Focus Might Change The Case For Investing In Insmed (INSM)
In recent days, Insmed drew attention as Raymond James initiated coverage highlighting the early Brinsupri launch, RBC Capital raised its expectations, and Vanguard Capital Management disclosed a passive 5.34% ownership stake of 11,514,893 shares as of March 31, 2026.
Together with upcoming healthcare conference presentations, this mix of supportive analyst commentary and increased institutional ownership points to rising market focus on Brinsupri’s commercial rollout and Insmed’s broader...